# NCT06403735 (NCT06403735)

> A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06403735
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Conditions: Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Solid Tumor
- Interventions: QLC1101
- Enrollment: 250
- Primary outcome: Dose limiting toxicity (DLT)
- Primary outcome: MTD (or MAD)
- Primary outcome: RP2D

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06403735